Juniper Pharma Services has entered into a long-term collaboration with OxSonics Ltd. to support the development, scale-up, and GMP manufacture of OxSonics’ sono-sensitive injectable particles.
 
When used in conjunction with new generation ultrasound devices, these injectable particles can be applied to a range of therapeutic applications including an oncological drug delivery platform called “SonoTran,” which is designed to enhance the delivery of anti-cancer drugs deep into solid tumors.
 
Dr. Colin Story, chief executive officer, OxSonics said, “Our technology has the genuine potential to deliver a step-change in the performance of a range of solid tumor cancer drugs. Taking the development of our proprietary sono-sensitive particles from a lab-scale to a clinical trial scale and grade is core to our development program and this is why we are working with Juniper Pharma Services.
 
“Given the innovative and novel nature of our ground-breaking technology, we need to work with a team of experts such as those at Juniper to develop and scale-up the manufacture of the technology. In addition, Juniper, on behalf of OxSonics, will manufacture the innovative technology for clinical studies.”
 
Dr. Nikin Patel, president at Juniper Pharma Services, said, “We are very pleased that OxSonics has chosen us as its long-term partner to help develop its pioneering platform. Dr. Story and his team have done a fantastic job to date and we trust our experts will add significant value to the project with regards to meeting future milestones.”
 
Formerly known as Molecular Profiles, Juniper Pharma Services unveiled its new name earlier this year to coincide with the rebranding of its Boston-based parent company, Juniper Pharmaceuticals, Inc.The company provides GMP clinical manufacturing covering topical and oral dosage form products, including the supply of potent compounds and controlled drugs.